drugset / Trial / NCT03418922
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).
Timeline
- Start
- 2018-01-16
- Primary completion
- 2022-12-28
- Completion
- 2022-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |